Arnaiz
2001
Arnaiz JA, Carne X, Riba N, Codina C, Ribas J, Trilla A. The use of evidence
in pharmacovigilance. Case reports as the reference source for drug withdrawals.
European Journal of Clinical Pharmacology 2001; 57: 89-91.
Asaria
2006
Asaria P, MacMahon E. Measles in the United Kingdom: can we eradicate it
by 2010? BMJ 2006; 333: 890-895.
Chan
2004
Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence
for selective reporting of outcomes in randomized trials: comparison of
protocols to published articles. JAMA 2004; 291: 2457-2465.
Derry
2001
Derry S, Kong LY, Aronson JK. Incomplete evidence: the inadequacy of databases
in tracing published adverse drug reactions in clinical trials. BMC
Medical Research Methodology 2001; 1: 7.
Edwards
1999
Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting of adverse effects
in clinical trials should be improved: lessons from acute postoperative
pain. Journal of Pain and Symptom Management 1999; 18: 427-437.
Glasziou 2004
Glasziou P, Vandenbroucke JP, Chalmers I. Assessing the quality of research.
BMJ 2004; 328: 39-41.
Glasziou
2007
Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials
unnecessary? Picking signal from noise. BMJ 2007; 334: 349-351.
Golder
2006
Golder S, McIntosh HM, Duffy S, Glanville J, Centre for Reviews and Dissemination
and UK Cochrane Centre Search Filters Design Group. Developing efficient
search strategies to identify reports of adverse effects in MEDLINE and
EMBASE. Health Information and Libraries Journal 2006; 23: 3-12.
Herxheimer
2002
Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of
jet lag. Cochrane Database of Systematic Reviews 2002, Issue 2.
Art No: CD001520.
Ioannidis
2004
Ioannidis JPA, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K,
Moher D. Better reporting of harms in randomized trials: an extension
of the CONSORT statement. Annals of Internal Medicine 2004; 141:
781-788.
Jick
1977
Jick H. The discovery of drug-induced illness. New England Journal of
Medicine 1977; 296: 481-485.
Jüni
2004
Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of
cardiovascular events and rofecoxib: cumulative meta-analysis. The
Lancet 2004; 364: 2021-2029.
Kelly
2003
Kelly WN. The quality of published adverse drug event reports. Annals
of Pharmacotherapy 2003; 37: 1774-1778.
Koch-Weser
1977
Koch-Weser J, Sellers EM, Zacest R. The ambiguity of adverse drug reactions.
European Journal of Clinical Pharmacology 1977; 11: 75-78.
Lanctot
1995
Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple
algorithm for assessment of adverse drug events. Clinical Pharmacology
and Therapeutics 1995; 58: 692-698.
Loke
2004
Loke YK, Derry S, Aronson JK. A comparison of three different sources of
data in assessing the frequencies of adverse reactions to amiodarone.
British Journal of Clinical Pharmacology 2004; 57: 616-621.
Loke
2006
Loke YK, Price D, Derry S, Aronson JK. Case reports of suspected adverse
drug reactions--systematic literature survey of follow-up. BMJ
2006; 332: 335-339.
McIntosh
2004
McIntosh HM, Woolacott NF, Bagnall AM. Assessing harmful effects in systematic
reviews. BMC Medical Research Methodology 2004; 4: 19.
Miettinen
1983
Miettinen OS. The need for randomization in the study of intended effects.
Statistics in Medicine 1983; 2: 267-271.
Olsen
1999
Olsen H, Klemetsrud T, Stokke HP, Tretli S, Westheim A. Adverse drug reactions
in current antihypertensive therapy: a general practice survey of 2586
patients in Norway. Blood Pressure 1999; 8: 94-101.
Papanikolaou
2006
Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on
harms of medical interventions in randomized and nonrandomized studies.
Canadian Medical Association Journal 2006; 174: 635-641.
Schulz
2002
Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what.
The Lancet 2002; 359: 696-700.
Stricker
2004
Stricker BH, Psaty BM. Detection, verification, and quantification of adverse
drug reactions. BMJ 2004; 329: 44-47.
Vandenbroucke
2004
Vandenbroucke JP. When are observational studies as credible as randomised
trials? The Lancet 2004; 363: 1728-1731.
Vandenbroucke
2006
Vandenbroucke JP. What is the best evidence for determining harms of medical
treatment? Canadian Medical Association Journal 2006; 174: 645-646.
Venning
1982
Venning GR. Validity of anecdotal reports of suspected adverse drug reactions:
the problem of false alarms. British Medical Journal (Clinical Research
Edition) 1982; 284: 249-252.
Venning
1983
Venning GR. Identification of adverse reactions to new drugs. II (continued):
How were 18 important adverse reactions discovered and with what delays?
British Medical Journal (Clinical Research Edition) 1983; 286:
365-368.